Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.
The outcome of 34 women with anti-Yo-associated paraneoplastic cerebellar degeneration was reviewed. Three patients had not developed cancer after more than 4 years of follow-up. The only independent predictor for survival was the type of associated tumor (risk ratio, 1.79; 95% CI, 1.02 to 3.12). Median survival was 100 months for patients with breast cancer and 22 for those with gynecologic cancer. Although paraneoplastic cerebellar degeneration leads to the diagnosis of cancer in 63% of the patients, cancer progression was the cause of death in 52%.
Rojas
I
I
Services of Neurology, Ciutat Sanitaria Universitaria de Bellvitge, Hospitalet, Spain.
Graus
F
F
Keime-Guibert
F
F
Reñé
R
R
Delattre
J Y
JY
Ramón
J M
JM
Dalmau
J
J
Posner
J B
JB
D000328:Adult; D001943:Breast Neoplasms / Q000503:physiopathology; D005260:Female; D005833:Genital Neoplasms, Female / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D020362:Paraneoplastic Cerebellar Degeneration / Q000401:mortality / Q000503:physiopathology*; D011379:Prognosis; D016019:Survival Analysis; D013997:Time Factors